Symic Bio Raises $11M in Financing

healthcareSymic Bio, a San Francisco, CA-based biopharmaceutical company developing novel extracellular matrix targeting drugs, raised $11m in financing.

The round was led by Cell Innovation Partners (CIP), a healthcare venture fund started by ReproCELL and Shinsei Bank Group in Japan, with participation from existing investors.

The company intends to use the funds to used to advance its disease-modifying osteoarthritis drug, SB-061, into a global Phase 2b trial to be started in the latter half of 2019. Further, a global Phase 3 trial evaluating the potential for SB-030 to prevent vein graft failure in peripheral artery disease is also expected to start in 2020.

Led by CEO Ken Horne, Symic Bio is a biopharmaceutical company developing novel matrix-targeting therapeutics, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix.
It currently has two clinical candidates:
– SB-061, directed at disease modification and pain management in the treatment of osteoarthritis, and
– SB-030, targeting the prevention of peripheral vein graft failure.
In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system.



Join the discussion